Search: control-f. Print: control-p
Information for Authors
Mission
The mission of Annals of Internal Medicine is to promote excellence in the practice of internal medicine and in clinical research. We publish original research, guidelines, narrative and systematic reviews, and essays and commentary on a broad range of topics related to the care of adults and adolescents. Our intended readership includes clinicians, clinical researchers, managers, and other persons involved in providing medical care. We are most interested in papers that will influence practice and that address important advances in internal medicine. Annals circulation is over 90,000, and our impact factor is 17.5.
Manuscript Preparation
TOP | Manuscript Preparation | Specific Article Types | Manuscript Processing | Manuscript Publication | Authorship Issues | Research/Publication Ethics | References | Appendix
General Guidelines
General Considerations
Annals has several categories of articles, each with its own requirements (Table). We publish original research that addresses prevalence, causes, mechanisms, diagnosis, course, treatment, and prevention of disease. We consider various study types, including meta-analyses and cost-effectiveness analyses, as original research. We divide original research into two categories: Original Articles (3200 or fewer words) and Brief Communications (1500 or fewer words). Brief Communications usually address preliminary or limited results of original research, including case series and important case reports of new, serious adverse drug effects. We consider both narrative and systematic reviews. Narrative reviews are especially suitable for describing cutting-edge and evolving developments, and discussing those developments in light of underlying theory. Systematic reviews are especially suitable for critiquing and summarizing a body of evidence relevant to focused questions about diagnostic, prognostic, or therapeutic clinical practices. For narrative reviews, we ask that authors include a box listing 3 to 7 take-home points that link back to the original questions that the review set out to answer. We also publish guidelines, position papers, letters, and essays about controversial medical issues, medical history, medicine and public policy, and patients’ or physicians’ experiences of illness.
Requirements for all categories of articles largely conform to the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals,” developed by the International Committee of Medical Journal Editors (ICMJE). Authors should write for a sophisticated general medical readership; follow principles of clear scientific writing (Gopen, Huth, CBESMC) and statistical reporting (Bailar, Lang); and prepare manuscripts according to recommended reporting guidelines and checklists (EQUATOR) whenever possible.
We consider only online submissions (click here to submit online). When submitting manuscripts, authors should also submit a copy of the original research protocol and other supplemental data as attachments if you think they would help the editors or reviewers to better understand the work. Include reprints of published papers and manuscripts of papers in press that contain data that appear in the submitted manuscript to help the editors form a judgment about the degree of duplicate publication (see Acknowledge Previous or Duplicate Publication and Duplicate Submission). Be prepared to provide original study data if requested by the editors.
Article Types TOP
| Section | Description | Word Limit | Abstract Type* | Miscellaneous Considerations |
| Original Research | Reports of original research on prevalence, causes, mechanisms, diagnosis, course, treatment, and prevention of disease. More details |
3200 | Structured 275 or fewer words |
Follow standard reporting guidelines - see links under specific article types. 75 or fewer bibliographic references; about 4 tables or figures. |
| Original Research: Brief Communications | Preliminary or limited results of original research on the causes, mechanisms, diagnosis, course, treatment, and prevention of disease. | 1500 | Structured 175 or fewer words |
20 or fewer bibliographic references; about 2 tables or figures. |
| Abroad | Reports on health care in countries other than the United States. More details |
2000 | Unstructured 175 or fewer words |
10 or fewer bibliographic references; 1 table or figure. |
| Academia and Clinic | Descriptions and evaluations of innovations in medical education, training, and research methodology. More details |
1500-4000 depending on article type | Structured or unstructured depending on article type | |
| Ad Libitum | Poetry. More details |
80 lines | None | |
| Clinical Guidelines and Position Papers | Summaries of official or consensus positions on issues related to clinical practice, health care delivery or public policy. More details |
4000 | Unstructured 275 or fewer words |
Include procedures used to formulate guideline recommendations and a bibliography of sources upon which the guideline recommendations are based. |
| Editorials | Commentary on current topics or on papers published elsewhere in the issue. More details |
1200 | None | 20 or fewer bibliographic references; no tables or figures; most are solicited by the Editors. |
| History of Medicine | Essays, reports, or biographic sketches on the evolution or language of medicine. More details |
3200 | Unstructured 275 or fewer words |
|
| Improving Patient Care | Reports of original research, reviews, and perspectives on improving the quality of patient care and avoiding medical errors. More details |
1500-4000 depending on article type | Structured or unstructured depending on article type | |
| In the Balance | Views on unsettled questions of diagnosis and treatment, particularly questions arising on common, important clinical problems. More details |
2000 | Unstructured 175 or fewer words |
Usually includes two papers presenting differing views and may be accompanied by an editorial; are often solicited by the Editors; 20 or fewer bibliographic references. |
| Letters: Clinical Observations | Short research or case reports. More details |
600 | None | If you report an adverse drug reaction (ADR), follow reporting guidelines for ADRs (see Edwards). Maximum of 5 authors and 5 references. |
| Letters: Comments and Response | Comments and Response on papers published in Annals. More details |
400 | None | Maximum of 3 authors and 5 references. |
| Medicine and Public Issues | Papers on the economic, ethical, sociologic, or political environment in medicine. More details |
2500 | Unstructured 175 or fewer words |
|
| On Being a Doctor | Short essays on illuminating experiences in practice. More details |
1500 | None | Fiction is welcome. |
| On Being a Patient | Short essays by physicians on their own experiences of illness and accounts written by patients or their families. More details |
1500 | None | Fiction is welcome. |
| Perspective | Essays representing opinions, presenting hypotheses, or considering controversial issues. More details |
1500 | Unstructured 175 or fewer words |
20 or fewer bibliographic references; about 2 tables or figures. |
| Reviews: Narrative | Descriptions of cutting-edge and evolving developments, and underlying theory. More details |
4000 | Unstructured 275 or fewer words |
Include a box (summary table) that lists concisely 3 to 7 take-home points of the review. |
| Reviews: Systematic & Meta-Analyses | Reviews that systematically find, select, critique, and synthesize evidence relevant to well-defined questions about diagnosis, prognosis, or therapy. More details |
4000 | Structured 275 or fewer words |
Include a flow diagram that depicts search and selection processes, and evidence tables. |
| Personae | Photographs that capture the personality of people (adults) in the context of their daily lives. More details |
None | Submit vertically-oriented black-and-white photographs; must obtain written permission from the subject(s); photographs are not returned. | |
Manuscript Format and Style TOP
Guidelines and checklists are available for the reporting of essential elements of many types of manuscripts. These guidelines are linked in the Article Types and Specific Article Types sections of the Information for Authors. We expect authors to include the elements suggested by the guidelines and checklists as appropriate
We advise authors to arrange components of manuscripts in the following order (see below for further instructions): title page, abstract, text, acknowledgements (if any), references, tables in numerical sequence, figure legends, figures in numerical sequence, and appendices (if any). Number all pages consecutively, starting with the title page. List the word count of the text of the manuscript at the bottom of the title page. Double space the text of the manuscript.
Do not use abbreviations unless absolutely necessary; do abbreviate long names of chemical substances and terms for therapeutic combinations, such as MOPP. Abbreviate names of tests and procedures that are better known by their abbreviations than by the full name (VDRL test, SMA-12). Abbreviate units of measurement when they appear with numerals (…measured in milliliters, but 10 mL). Use abbreviations in figures and tables to save space. Explain all abbreviations used in the figure legend or table footnote.
Use generic names for all drugs. You may refer to an instrument by its proprietary name; give the name and location of the manufacturers in parentheses in the text. Use SI units throughout (Young). When reporting values for commonly studied components (α1-antitrypsin, ammonia, bilirubin, calcium, cholesterol, creatinine, creatinine clearance, digoxin, estradiol, glucose, iron, iron-binding capacity, lead, lipids [total], lipoproteins, magnesium, phosphate, testosterone, thyroxine [T4], triglycerides, and urea nitrogen), report the value in SI units with traditional units given in parentheses.
Title Page TOP
Title: Give the main title and subtitle (if any). If the study is a randomized trial, add that descriptor as the subtitle at the end of the title. If it is a systematic review, narrative review, or meta-analysis, put that information at the beginning of the title, followed by a colon. Use titles that stimulate interest, are easy to read and concise (12 words or fewer), and contain enough information to convey the essence of the article. Also provide a short or “running” title of 7 or fewer words.
Authors: List authors in the order in which they are to appear in the byline of the published article. In the case of group authorship, identify one or more authors who will have responsibility for the publication. Give the institutional affiliation for each author, financial support information, contact information for the corresponding author, and contact information for the author to receive reprint requests.
Word Count: List the word count for the text of the manuscript. Don’t include the abstract or the references in word counts.
Abstracts TOP
Abstracts should accompany all submissions except Editorials, On Being a Doctor/On Being a Patient pieces, and Clinical Observations (research letters). Use unstructured formats and limits of 175 or fewer words for abstracts of the following: Perspective, In the Balance, Abroad, and Medicine and Public Policy. Use unstructured formats and limits of 275 or fewer words for abstracts of Narrative Reviews, Position Papers, and History of Medicine. Use structured abstracts of 275 or fewer words for Original Research (Brief Communications 175 or fewer words), Cost-Effectiveness Studies, and Systematic Reviews, including Meta-analyses (Cook, Haynes). Organize structured abstracts for these articles, as shown below.
Original Research
Background, Objective, Design, Setting, Patients, Intervention (if any), Measurements, Results, Limitations, Conclusions. If the study is a randomized, controlled trial, list where the trial is registered and the trial’s unique registration number at the end of the abstract.
Cost-Effectiveness Studies
Background, Objective, Design, Data Sources, Target Population, Time Horizon, Perspective, Interventions, Outcome Measures, Results of Base-Case Analysis, Results of Sensitivity Analysis, Limitations, Conclusions.
Systematic Reviews, including Meta-analyses
Background, Purpose, Data Sources, Study Selection, Data Extraction, Data Synthesis, Limitations, Conclusions.
Manuscript Text TOP
For original articles, economic analyses, systematic reviews, and meta-analyses, use four main headings when arranging text: Introduction, Methods, Results, and Discussion. Aim for clear, concise, logically organized presentations. Use active voice whenever possible. Specific guidance ON content follows.
Introduction: Use short introductions that concisely set up the context of the research for readers. Always end the introduction with a clear statement of the study’s objectives or hypotheses.
Methods: For studies involving humans, describe in the Methods section how participants were assembled and selected, and the sites or setting from which they were recruited. Then describe study procedures including any interventions, measurements and data collection techniques. Use figures to diagram study processes including the flow of participants through the study. Provide the number of patients at each stage of recruitment and follow-up, including the number who declined to participate and the number who completed follow-up. State, if true, that an institutional review board approved the study or affirm that the protocol is consistent with the principles of the Declaration of Helsinki (World Medical Association), and state whether participants gave their informed consent. For studies that have numerical data and use statistical inference, include a section under Methods that describes the methods used for the statistical analysis and that states the specific statistical software. For all studies, include a statement at the end of the Methods section describing the role of the funding source for the study. If the study had no external funding source or if the funding source had no role in the study, state so explicitly.
Results: Fully describe the study sample so that readers can gauge how well the study findings apply to their patients (external validity). Then present primary findings followed by any secondary and subgroup findings. Use tables and figures to demonstrate main characteristics of participants and major findings. Avoid redundancy between text and tables and figures.
Discussion: Consider structuring the discussion according to the following sequence.
- Provide a brief synopsis of key findings, with particular emphasis on how the findings add to the body of pertinent knowledge.
- Discuss possible mechanisms and explanations for the findings.
- Compare study results with relevant findings from other published work. Briefly state literature search sources and methods (e.g., English-language MEDLINE search to Jan 2007) that identified previous pertinent work. Use tables and figures to help summarize previous work when possible.
- Discuss the limitations of the present study and any methods used to minimize or compensate for those limitations.
- Mention any crucial future research directions.
- Conclude with a brief section that summarizes in a straightforward and circumspect manner the clinical implications of the work.
Acknowledgments TOP
Acknowledge only persons who have contributed to the scientific content or provided technical support. Authors should obtain written permission from anyone they wish to list in the Acknowledgments section. The corresponding author must also affirm that he or she has listed everyone who contributed significantly to the work in the Acknowledgments.
References TOP
- Number references, using Arabic numerals in parentheses, in the order in which they first appear in the text. References cited in a table/figure should appear in numeric order relative to the first citation of the table/figure in the text. For example, if the last reference cited before the table/figure in question is mentioned as reference 14, and that table/figure contains 5 references that have not been cited, the references in the table/figure would be numbered 15 through 19. Reference citations in the text would then recommence with number 20.
- Appendix material should not have separate reference sections. References that appear in both the text and the appendix should be numbered as they appear in the text. Any references that appear only in the appendix should be added consecutively to the end of the text reference list.
- Use the reference style of the National Library of Medicine, including the abbreviations of journal titles.
- List all authors when there are 6 or fewer; when there are 7 or more authors, list only the first 6 and add “et al.”
- Do not use ibid. or op cit.
- Include an “available from” note for documents that may not be readily accessible.
- Cite symposium papers only from published proceedings.
- When citing an article or book accepted for publication but not yet published, include the title of the journal (or name of the publisher) and the year of expected publication.
- Include references to unpublished material in the text, not in the references (for example, papers presented orally at a meeting; unpublished work [personal communications, papers in preparation]), and submit a letter of permission from the cited persons to cite such communications (in general, avoid citations to unpublished scientific results).
- Ensure that URLs used as references are active and available (the references should include the date on which the author accessed the URL) (see also Badgett ‘In Reply’).
Click here for sample references that conform to the style specified by the Uniform Requirements agreement.
Footnotes TOP
Use footnotes only on the title page and in tables. Do not use footnotes in the text. Footnote symbols, in the order in which they should be used, are *, †, ‡, §, ||, ¶, **, ††, ‡‡, and so on. Do not use numbers or letters.
Tables TOP
Number tables with Arabic numerals in the order in which they appear in the text. Tables that are meant as appendix material should be numbered as Appendix Table 1, Appendix Table 2, and so on. Use titles that concisely describe the content of the table so that a reader can understand the table without referring to the text. Tables may contain abbreviations that we do not permit in the text, but the table should contain a footnote that explains the abbreviation. Give the units of measure for all numerical data in a column or row. Place units of measure under a column heading or at the end of a side heading only if those units apply to all numerical data in the column or row.
Figures TOP
Number figures with Arabic numerals in the order in which they appear in the text. Figures that are meant as appendix material should be numbered as Appendix Figure 1, Appendix Figure 2, and so on. Each figure should have a figure legend that begins with a short title. Reduce the length of legends by using phrases rather than sentences. Explain all abbreviations and symbols on the figure, even if an explanation appears in the text. For pictures of histologic slides, give stain and magnification data at the end of the legend for each part of the figure. If no scale marker appears on the figure, give the original magnification used during the observation, not that of the photographic print.
Acknowledgements to original sources of borrowed material should use the wording specified by the original publisher of the material. If there is no specified wording, cite the authors, reference number, and the publisher. Letters of permission from the copyright holder must accompany submission of borrowed material.
Statistical Guidelines
| Presentation | |
| Issue | Notes |
| Percentages | Report percentages to one decimal place (i.e., xx.x%) when sample size is >=200.
To avoid the appearance of a level of precision that is not present with small samples, do not use decimal places (i.e., xx%, not xx.xx%) when sample size is < 200. |
| Standard deviations | Use “mean (SD)” rather than “mean ± SD” notation. The ± symbol is ambiguous and can represent standard deviation or standard error. |
| Standard errors | Report confidence intervals, rather than standard errors, when possible. |
| P values | Report exact P values to two decimal places except when P<0.001, in which case “p<0.001” is sufficient. |
| “Trend” | Use the word trend when describing a test for trend or dose-response.
Avoid the term trend when referring to P values near but not below 0.05. In such instances, simply report a difference and the confidence interval of the difference (if appropriate) with or without the P value. |
| Statistical software | Specify in the statistical analysis section the statistical software—version, manufacturer, and manufacturer’s location—used for analyses. |
| Cox models | When reporting the findings from Cox proportional hazards models:
|
| Descriptive tables | In tables that simply describe characteristics of 2 or more groups (e.g., Table 1 of a clinical trial):
|
| Tables reporting multivariable analyses | Authors sometimes present tables that compare one by one an outcome with multiple individual factors followed by a multivariable analysis that adjusts for confounding. If confounding is present, as is often the case, the one-way comparisons are simply intermediate steps that offer little useful information for the reader. In general, omit presenting these intermediate steps in the manuscript and do not focus on them in the Results or Discussion. |
| Tables and figures (general) |
The following references give useful information about the design and format of informative tables and figures: Tufte ER. The Visual Display of Quantitative Information. Cheshire CT: Graphic Press; 1983, p 178. ISBN: 0961392142 Wainer, H. How to display data badly. The American Statistician 1984; 38:137-147. Google Scholar Wainer H. Visual Revelations: graphical tales of fate and deception from Napoleon Bonaparte to Ross Perot. New Jersey: Lawrence Erlbaum Associates, Inc.;1997. ISBN: 038794902X Pocock SJ, Clayton TC, Altman DG. Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls. Lancet 2002; 359:1686-89. PMID: 12020548 Also, follow a few simple rules of thumb:
|
Multivariable Analysis TOP
Screening covariates
Approaches that select factors for inclusion in a multivariable model only if the factors are “statistically significant” in “bivariate screening” are not optimal. A factor can be a confounder even if it is not statistically significant by itself because it changes the effect of the exposure of interest when it is included in the model, or because it is a confounder only when included with other covariates.
Reference
Sun GW, Shook TL, Kay GL. Inappropriate use of bivariable analysis to screen risk factors for use in multivariable analysis. J Clin Epidemiol. 1996;49:907-16. PMID: 8699212
Model building
Authors should avoid stepwise methods of model building, except for the narrow application of hypothesis generation for subsequent studies. Stepwise methods include forward, backward, or combined procedures for the inclusion and exclusion of variables in a statistical model based on predetermined P value criteria. Better strategies than P value driven approaches for selecting variables are those that use external clinical judgment. Authors might use a bootstrap procedure to determine which variables, under repeated sampling, would end up in the model using stepwise variable selection procedures. Regardless, authors should tell readers how model fit was assessed, how and which interactions were explored, and the results of those assessments.
References
Collett D, Stepniewska K. Some practical issues in binary data analysis. Statist Med. 1999;18:2209-21. PMID: 10474134
Mickey RM, Greenland S. The impact of confounder selection criteria on effect estimation. Am J Epidemiol. 1989;129:125-37. PMID: 2910056
Steyerberg EW, Eijkemans MJC, Harrell FE, Jr., Habbema JDF. Prognostic modeling with logistic regression analysis: a comparison of selection and estimation methods in small data sets. Statist Med. 2000;19:1059-1079. PMID: 10790680
Steyerberg EW, Eijkemans MJC, Habbema DF. Stepwise selection in small data sets: a simulation study of bias in logistic regression analysis. J Clin Epidemiol. 1999;52:935-42. PMID: 10513756
Altman D, Andersen PK. Bootstrap investigation of the stability of a Cox regression model. Statist Med. 1989;8:771-83. PMID: 2672226
Mick R, Ratain MJ. Bootstrap validation of pharmacodynamic models defined via stepwise linear regression. Clin Pharmacol Ther. 1994;56:217-22. PMID: 8062499
Harrell FE, Jr, et al. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Statist Med. 1996;15:361-87. PMID: 8668867
Measurement Error
If several risk factors for disease are considered in a logistic regression model and some of these risk factors are measured with error, the point and interval estimates of relative risk corresponding to any of these factors may be biased either toward or away from the null value; the direction of bias is never certain. In addition to potentially biased estimates, confidence intervals of correctly adjusted estimates will be wider, sometime substantially, than naïve confidence intervals. Authors are encouraged to consult the references below for strategies to address this problem.
References
Rosner B, Spiegelman D, Willett WC. Correction of logistic regression relative risk estimates and confidence intervals for measurement error: the case of multiple covariates measured with error. Am J Epidemiol. 1990;132:734-45. PMID: 2403114
Carroll R. Measurement Error in Epidemiologic Studies. In Encyclopedia of Biostatistics. New York: John Wiley & Sons; 1998. ISBN: 0471975761.
Measures of Effect and Risk TOP
Clinically meaningful estimates
Authors should report results for meaningful metrics rather than reporting raw results. For example, rather than reporting the log odds ratio from a logistic regression, authors should transform coefficients into the appropriate measure of effect size, odds ratio, relative risk, or risk difference. Don’t give readers an estimate, such as an odds ratio or relative risk, for a one unit change in the factor of interest when a 1-unit change lacks clinical meaning (age, mm Hg of blood pressure, or any other continuous or interval measurement with small units). All estimates should reflect a clinically meaningful change, along with 95% confidence bounds.
Between-group differences
For comparisons of interventions (e.g., trials), focus on between- group differences, with 95% confidence intervals of the differences, and not on within-group differences. State the results using absolute numbers (numerator/denominator) when feasible. When discussing effects, refer to the confidence intervals rather than P values and point out for readers if the confidence intervals exclude the possibility of significant clinical benefit or harm.
Odds ratios and predicted probabilities
Authors often report odds ratios for multivariable results when the odds ratio is difficult to interpret or not meaningful. First, the odds ratio might overstate the effect size when the reference risk is high. For example, if the reference risk is 25% (odds = 0.33) and the odds ratio is 3.0, the relative risk is only 2.0. Statements such as “3-fold increased risk” or “3 times the risk” are incorrect. Second, readers want an easily understood measure of the level of risk (and the confidence intervals) for different groups of patients as defined by treatment, exposure, and covariates. Consider providing a table of predicted probabilities for each of the factors of interest, and confidence intervals of those predicted probabilities. Moreover, a multiway table that cross classifies predicted probabilities by the most important factor and then adjusts for the remaining factors will often be more meaningful than a table of adjusted odds ratios. Standard commercial software can produce predicted probabilities and confidence bounds.
Reference
Altman DG, Deeks JJ, Sackett DL. Odds ratios should be avoided when events are common. BMJ. 1998;317:1318. PMID: 9804732
Missing Data TOP
Missing variables
Always report the frequency of missing variables and how the analysis handled missing data. Consider adding a column to tables or a row under figures that makes clear the amount of missing data. Avoid using a simple indicator or dummy variable to represent a missing value. Replacing missing predictors with dummy variables or missing indicators generally leads to biased estimates.
References
Vach W, Blettner M. Biased estimation of the odds ratio in case-control studies due to the use of ad hoc methods or correcting for missing values of confounding variables. Am J Epidemiol. 1991;134:895-907. PMID: 1670320
Vach W, Blettner M. Missing data in epidemiologic studies. In Encyclopedia of Biostatistics. New York: John Wiley & Sons; 1998:2641-2654. ISBN: 0471975761
Greenland S, Finkle WD. A critical look at methods for handling missing covariates in epidemiologic regression analyses. Am J Epidemiol. 1995;142:1255-64. PMID: 7503045
Allison PD. Missing Data. Thousand Oaks, California: Sage Publications, Inc., 2002. ISBN: 0761916725
Missing Outcomes
Always report the frequency of missing outcomes and follow-up data; reasons and any patterns for the missing data; and how you handled missing data in the analyses. Do not use a last observation carried forward approach (LOCF) to address incomplete follow-up even if the original protocol prespecified that approach for handling missing data. LOCF approaches understate variability and result in bias. The direction of the bias is not predictable. Although the method of addressing missing data may have little import on findings when the proportion of missing data is small (e.g., <5%), authors should avoid using outdated or biased methods to address incomplete follow-up. Appropriate methods for handling missing data include imputation, pattern-mixture (mixed) models, and selection models. Application of these methods requires consideration of the patterns and potential mechanisms behind the missing data.
References
Fitzmaurice GM, Laird NM, Ware JH. Applied Longitudinal Analysis.
New York; John Wiley & Sons:2004:chapter 14. ISBN: 0471214876
Molenberghs G, Verbeke G. Models for Discrete Longitudinal Data.
New York: Springer;2005:chapters 26-32. ISBN: 0387251448
Longitudinal Analyses TOP
Consider using longitudinal analyses if outcome data were collected at more than 1 time point. With an appropriate model for longitudinal analysis, you can report differences within groups over time, differences between groups, and differences across groups of their within-group changes over time (usually the key contrast of interest). You can control for any confounding that might emerge, such as a difference in a variable (e.g., body weight) among those who remained in the study until completion. Longitudinal analysis options include a population averaged analysis (generalized estimating equations [GEEs], for example) that estimates the time by treatment interaction and adjusts variance for the repeated measures within individuals over time. Another option is a mixed effects model, with random effects for patient, and the estimate of interest being the time by treatment interaction. In choosing a model, consider whether any missing data are missing at random (i.e. “ignorable” missing data) or missing dependent on the observed data (i.e. informative missing data). In GEE analyses, missing data are assumed to be missing completely at random independent of both observed and unobserved data. In random coefficient analysis, missing data are assumed missing at random dependent on observed data but not on unobserved data.
Reference
Twisk JWR. Applied longitudinal data analysis for epidemiology: a practical guide. Cambridge University Press. New York 2003 ISBN: 0521819768
Specific Article Types
TOP | Manuscript Preparation | Specific Article Types | Manuscript Processing | Manuscript Publication | Authorship Issues | Research/Publication Ethics | References | Appendix
Specific Article Types: Original Research
Overview of Original Research Formats
Original research may be reported in a full-length article or a brief communication.
Full-length articles are reports of original research on the prevalence, causes, mechanisms, diagnosis, course, treatment, and prevention of disease.
- Word limit for abstract: 275 words
- Word limit for text: 3200 words (excluding Abstract and references)
Brief Communications are preliminary or limited results of original research studies, or are full reports of original research that can be conveyed in shortened form.
- Word limit for abstract: 175 words
- Word limit for text: 1500 words (excluding Abstract and references)
| Controlled Trials TOP | |
| Description: Reports of trials of interventions for the treatment, diagnosis, course, or prevention of disease. A trial may be reported in either a full-length article or a brief communication format. Recent examples | |
| Title | |
| Subtitle | For randomized trials, add the subtitle “A Randomized, Controlled Trial” to the full title of your manuscript. For example: “Effect of Increasing the Intensity of Implementing Pneumonia Guidelines: A Randomized, Controlled Trial”. |
| Abstract | |
| Word limit | 275 words |
| Structure | Background, Objective, Design, Setting, Patients, Intervention, Measurements, Results, Limitations, Conclusions (see Haynes, Hopewell). |
| Other | Specify where the trial is registered and the trial’s unique registration number at the end of the abstract (see Clinical Trials Registration). Also state the source of funding, if any. |
| Manuscript | |
| Guidelines and checklists |
All RCTs: CONSORT standards (see Moher, Hopewell) and extension for reporting adverse outcomes (see Ioannidis)
Cluster RCTs: CONSORT standards for cluster RCTs (see Campbell) Herbal intervention RCTs: CONSORT Statement elaboration (see Gagnier) Nonpharmacologic RCTs: Consort extension (see Boutron) Noninferiority and equivalence RCTs: CONSORT Statement extension (see Piaggio) |
| Word limit | 3200 words (excluding abstract and references) |
| Sections |
Introduction, Methods, Results, and Discussion.
Use the following methods section subheadings:
|
| References | 75 or fewer |
| Tables and figures |
About 6
Include a CONSORT flow diagram. |
| Comments |
Always end the introduction section with a clear statement of the study’s objectives or hypotheses.
Identify the funding source for the study, and its role in the study’s design, conduct, and reporting. Put this information under the last subhead of the Methods section and title the subhead Role of the Funding Source. Confirm that the study was approved by an Institutional Review Board. If the study was not submitted to an Institutional Review Board, provide documentation that not seeking Institutional Review Board review for this type of study was in accordance with the policy of your institution. |
| Other | |
| Protocol | Submit the trial protocol that was approved by the institutional review board and subsequent amendments. Make sure that these documents are dated appropriately. |
| Statistical analysis | Save and be prepared to submit statistical code and output from data analyses if the editors so request. |
| Data | To check or clarify analyses and findings, editors may ask researchers to provide the raw data for their studies during review or at any time up to 5 years after publication in Annals. |
Clinical Trials Registration TOP
All clinical trials must be registered in a public registry prior to submission. We follow the trials registration policy of the International Committee of Medical Journal Editors (www.ICMJE.org) and consider only trials that have been appropriately registered before submission, regardless of when the trial closed to enrollment. Acceptable registries must meet the following ICMJE requirements: be publicly available, searchable, and open to all prospective registrants; have a validation mechanism for registration data; and be managed by a not-for-profit organization.
As defined by the ICMJE, a clinical trial is any research project that prospectively assigns human subjects to intervention and comparison groups to study the cause-and-effect relationship between a medical intervention and a health outcome. A medical intervention is any intervention used to modify a health outcome, and includes but is not limited to drugs, surgical procedures, devices, behavioral treatments, and process-of-care changes. A trial must have at least 1 prospectively assigned concurrent control or comparison group in order to trigger the requirement for registration. Nonrandomized trials are not exempt from the registration requirement if they meet the above criteria.
| Observational Studies TOP | |
| Description: Reports of cohort, case-control, and cross-sectional studies of the prevalence, causes, mechanisms, diagnosis, course, treatment, and prevention of disease. | |
| Abstracts | |
| Word limit | 275 words |
| Structure | Background, Objective, Design, Setting, Patients, Measurements, Results, Limitations, Conclusions (see Haynes). |
| Manuscript | |
| Guidelines and checklists | STROBE statement and checklist (See von Elm and Vandenbroucke) |
| Word limit | 3200 words (excluding abstract and references) |
| Sections | Introduction, Methods, Results, and Discussion |
| References | 75 or fewer |
| Tables and figures | About 6 |
| Comments | Always end the introduction section with a clear statement of the study’s objectives or hypotheses.
Identify the funding source for the study, and its role in the study’s design, conduct, and reporting. Put this information under the last subhead of the Methods section and title the subhead Role of the Funding Source. In the Methods section, state (if correct) that the study was approved by an Institutional Review Board. If the study was not submitted to an Institutional Review Board, provide documentation that not seeking Institutional Review Board review for this type of study was in accordance with the policy of your institution. |
| Other | |
| Protocol | We encourage submission of the original study protocol. |
| Statistical analysis | Save and be prepared to submit statistical code and output from data analyses if the editors so request. |
| Data | To check or clarify analyses and findings, editors may ask researchers to provide the raw data for their studies during review or at any time up to 5 years after publication in Annals. |
| Diagnostic Test Studies TOP | |
| Description: Reports of studies of the accuracy of diagnostic tests. Recent examples | |
| Title | |
| Title | Identify the article as a study of diagnostic accuracy somewhere in the Title. |
| Abstracts | |
| Word limit | 275 words |
| Structure | Background, Objective, Design, Setting, Patients, Measurements, Results, Limitations, Conclusions (see Haynes). |
| Manuscript | |
| Guidelines and checklists | Consult STARD guidelines and checklist (see Bossuyt). |
| Word limit | 3200 words (excluding abstract and references) |
| Sections | Introduction, Methods, Results, and Discussion. |
| References | 75 or fewer |
| Tables and figures |
About 6
Include a STARD flow diagram (see Bossuyt). |
| Comments |
Always end the introduction section with a clear statement of the study’s objectives or hypotheses.
Identify the funding source for the study, and its role in the study’s design, conduct, and reporting. Put this information under the last subhead of the Methods section and title the subhead Role of the Funding Source. Confirm that the study was approved by an Institutional Review Board. If the study was not submitted to an Institutional Review Board, provide documentation that not seeking Institutional Review Board review for this type of study was in accordance with the policy of your institution. |
| Other | |
| Protocol | We encourage submission of the original study protocol. |
| Statistical analysis | Save and be prepared to submit statistical code and output from data analyses if the editors so request. |
| Data | To check or clarify analyses and findings, editors may ask researchers to provide the raw data for their studies during review or at any time up to 5 years after publication in Annals. |
| Cost-Effectiveness Studies TOP | |
| Description: Reports of comparisons of the relative costs and benefits of two or more interventions intended to prevent, diagnose, or treat disease. Recent examples | |
| Title | |
| Subtitle | For studies of cost-effectiveness, identify the article as a cost-effectiveness analysis. |
| Abstracts | |
| Word limit | 275 words |
| Structure | Background, Objective, Design, Data Sources, Target Population, Time Horizon, Perspective, Interventions, Outcome Measures, Results of Base-Case Analysis, Results of Sensitivity Analysis, Limitations, Conclusions (see Haynes). |
| Manuscript | |
| Guidelines and checklists | We recommend authors of these reports to include the elements suggested by published guidelines (see Siegel, also Philips, Sculpher, Weinstein.) |
| Word limit | 3200 words (excluding abstract and references) |
| Sections | Introduction, Methods, Results, and Discussion |
| References | 75 or fewer |
| Tables and figures | About 6 |
| Comments |
Always end the introduction section with a clear statement of the study’s objectives or hypotheses.
Identify the funding source for the study, and its role in the study’s design, conduct, and reporting. Put this information under the last subhead of the Methods section and title the subhead Role of the Funding Source. Confirm that the study was approved by an Institutional Review Board. If the study was not submitted to an Institutional Review Board, provide documentation that not seeking Institutional Review Board review for this type of study was in accordance with the policy of your institution. |
| Other | |
| Statistical analysis | Save and be prepared to submit statistical code and output from data analyses if the editors so request. |
| Data | To check or clarify analyses and findings, editors may ask researchers to provide the raw data for their studies during review or at any time up to 5 years after publication in Annals. |
Specific Article Types: Reviews
| Systematic Reviews and Meta-analyses TOP | |
| Description: Reviews that systematically find, select, critique, and synthesize evidence relevant to well-defined questions about diagnosis, prognosis, or therapy. Recent examples | |
| Title | |
| Subtitle | For studies that are meta-analyses or systematic reviews, add that descriptor as the subtitle at the end of the title. |
| Abstracts | |
| Word limit | 275 words |
| Structure | Background, Purpose, Data Sources, Study Selection, Data Extraction, Data Synthesis, Limitations, Conclusions (see Mulrow, Haynes). |
| Manuscript | |
| Guidelines and checklists |
For meta-analyses of randomized, controlled trials, follow PRISMA reporting guidelines and checklist.
For meta-analyses of observational studies in epidemiology, follow MOOSE reporting guidelines and checklist. |
| Word limit | 3500 words (excluding abstract and references) |
| Sections |
Introduction, Methods, Results, and Discussion.
The methods section subheadings should be:
|
| References | 75 or fewer |
| Tables and figures |
4 or fewer
Include a flow diagram that depicts search and selection processes, and evidence tables. |
| Comments |
Always end the introduction section with a clear statement of the study’s objectives or hypotheses.
For studies that have numerical data and use statistical inference, include a section under Methods that describes the methods and specific statistical software used for the statistical analysis. |
| Narrative Reviews TOP | |
| Description: Narrative reviews are especially suitable for describing cutting-edge and evolving developments, and discussing those developments in light of underlying theory. Recent Examples | |
| Abstracts | |
| Word limit | 275 words |
| Unstructured | |
| Manuscript | |
| Guidelines | Consult Annals editors’ guidelines for narrative reviews (see Editors). |
| Word limit | 3500 words (excluding abstract and references) |
| Tables and figures | 4 or fewer |
| References | 75 or fewer |
| Comments | Include a box listing 3 to 7 take-home points that link back to the original questions that the review set out to answer. |
Specific Article Types: Letters
| Clinical Observations TOP | |
| Description: Clinical Observations may be original research presented in a research letter format or case reports or series. If an author believes that the case report or case series is important enough to warrant publication as a Brief Communication (up to 1500 words), they should contact the Editor for advice about which format to use.
(Of note, readers who wish to comment on published articles should use the Rapid Response mechanism.) |
|
| Manuscript | |
| Guidelines and checklists | If you report an adverse drug reaction (ADR), follow reporting guidelines for ADRs (see Edwards). |
| Word limit | 600 words (excluding references) |
| Sections | Background, Objective, Methods and Findings (or Case Report, as applicable), Discussion, and References |
| References | 5 or fewer |
| Tables and figures | Maximum of 1 table or figure |
| Comments | Maximum of 5 authors |
| Rapid Responses TOP | |
| Description: "Letter to the editor" in response to a published article. | |
| Abstracts | |
| Abstract | None |
| Manuscript | |
| Word limit | 400 words (excluding references) |
| References | 5 or fewer |
| Tables and figures | None |
| Authors | Maximum of 3 authors |
| Other details |
![]()
|
Specific Article Types: Other
| Abroad TOP | |
| Description: Reports on health care in countries other than the United States. Recent examples | |
| Abstracts | |
| Word limit | 175 words |
| Structure | Unstructured |
| Manuscript | |
| Word limit | 2000 words (excluding abstract and references) |
| References | 10 or fewer |
| Tables and figures | Limit is 1 |
| Academia and Clinic TOP | |
| Description: Descriptions and evaluations of innovations in medical education, training, and research methodology. Academia and Clinic may take a variety of forms including original research, narrative or systematic reviews, guidelines, or points of view (perspectives). Narrative reviews are especially suitable for describing cutting-edge and evolving developments, and discussing those developments in light of underlying theory. Systematic reviews are especially suitable for critiquing and summarizing a body of evidence relevant to focused questions about diagnostic, prognostic, or therapeutic clinical practices.
For further instructions, please click one of the links above. Recent examples |
|
| Abstracts | |
| Word limit | |
| Structure | Unstructured or structured depending on article type |
| Manuscript | |
| Word limit | 1500-4000 depending on article type (excluding abstract and references) |
| References | No limit |
| Tables and figures | No limit |
| Other | |
| Statistical analysis | Save and be prepared to submit statistical code and output from data analyses if the editors so request. |
| Data | To check or clarify analyses and findings of articles with original data, editors may ask researchers to provide the raw data for their studies during review or at any time up to 5 years after publication in Annals. |
| Ad Libitum TOP | |
| Description: Poetry. Recent examples | |
| Manuscript | |
| Maximum length | 80 lines |
| Editorials TOP | |
| Description: Commentary on current topics or on papers published elsewhere in the issue. Recent examples | |
| Abstracts | |
| Abstract | None |
| Manuscript | |
| Word limit | 1000 words (excluding references) |
| References | 20 or fewer |
| Tables and figures | Limit is 1 |
| Comments | Most editorials published in Annals are solicited by the Editors. |
| Clinical Guidelines and Position Papers TOP | |
| Description: Summaries of official or consensus positions on issues related to clinical practice, health care delivery, or public policy. Recent examples | |
| Abstracts | |
| Word limit | 275 |
| Structure | Unstructured |
| Manuscript | |
| Guidelines and checklists | We expect authors of reports in one of these categories to include the elements suggested by the guidelines (see GRADE, Shiffman). |
| Word limit | 4000 words (excluding references) |
| Comments | Include descriptions of procedures used to formulate guideline recommendations and a bibliography of sources upon which the guideline recommendations are based |
| History of Medicine TOP | |
| Description: Essays, reports, or biographic sketches on the evolution of medicine. Recent examples | |
| Abstract | |
| Word limit | 275 words |
| Structure | Unstructured |
| Manuscript | |
| Word limit | 3200 words (excluding abstract and references) |
| References | No limit |
| Tables and figures | No limit |
| Improving Patient Care TOP | |
| Description: Reports of original research, reviews, and perspectives on improving the quality of patient care and avoiding medical errors. Recent examples | |
| Abstract | |
| Word limit | |
| Structure | Unstructured or structured depending on article type |
| Manuscript | |
| Word limit | 1500-4000 depending on article type |
| References | No limit |
| Tables and figures | No limit |
| Other | |
| Statistical analysis | Save and be prepared to submit statistical code and output from data analyses if the editors so request. |
| Data | To check or clarify analyses and findings of articles with original data, editors may ask researchers to provide the raw data for their studies during review or at any time up to 5 years after publication in Annals. |
| In the Balance TOP | |
| Description: Views on unsettled questions of diagnosis and treatment, particularly questions arising on common, important clinical problems. Recent examples | |
| Abstracts | |
| Word limit | 175 words |
| Structure | Unstructured |
| Manuscript | |
| Word limit | 1500 words (excluding abstract and references) |
| References | 20 or fewer bibliographic references |
| Tables and figures | No limit |
| Comments |
Usually includes 2 papers presenting differing views.
May be accompanied by an editorial; solicited by the editors. |
| Medicine and Public Issues TOP | |
| Description: Papers on the economic, ethical, sociologic, or political environment in medicine. Recent examples | |
| Abstracts | |
| Word limit | 175 words |
| Structure | Unstructured |
| Manuscript | |
| Word limit | 2500 words (excluding abstract and references) |
| References | No limit |
| Tables and figures | No limit |
| On Being A Doctor/On Being A Patient TOP | |
| Description: Short essays on illuminating experiences of physicians or patients. Physicians, patients, and their families are invited to submit essays. Authors should specify in a cover letter whether the essay is nonfiction, fiction, or a fictionalized account of true events. If the essay is nonfiction, we ask that the authors mask the identity of people. In addition, the editors feel it is important for authors to show the manuscript to those described in the essay and to obtain their permission to publish the material. Annals does not require signed permission from the subjects of essays, but we do require the authors to state in writing whether they obtained the subjects’ permission. If the author has not obtained permission, he or she should explain the reasons for its absence in a cover letter that accompanies the manuscript. We publish nonfiction material that does not have the subject’s permission at the editors’ discretion. Recent examples | |
| Manuscript | |
| Word limit | 1500 words |
| Personae TOP | |
| Description: Photographs that capture the personality of people (adults) in the context of their daily lives. | |
| Comment | Submit vertically oriented black-and-white photographs. If accepted, the photographs must be re-submitted on a compact disk in JPG or TIF format at print-quality resolution (i.e., no less than 400 pixels at 2 inches wide, preferably at least 600 pixels at 2 inches wide). The photographer must obtain written permission from the subject(s); photographs are not returned. |
| Perspective TOP | |
| Description: Essays representing opinions, presenting hypotheses, or considering controversial issues. | |
| Abstracts | |
| Word limit | 175 words |
| Structure | Unstructured or structured depending on article type |
| Manuscript | |
| Word limit | 1500 words (excluding abstract and references) |
| References | 20 or fewer bibliographic references |
| Tables and figures | About 2 tables or figures |
Manuscript Processing
TOP | Manuscript Preparation | Specific Article Types | Manuscript Processing | Manuscript Publication | Authorship Issues | Research/Publication Ethics | References | Appendix
Fast-Track Publication
We will consider manuscripts for expedited review and early publication if they are of very high quality, if they have findings that are likely to affect practice immediately, and if rapid publication would probably minimize adverse patient care consequences. We will give particular priority for fast-tracking to large clinical trials. If authors think that their manuscript warrants fast-tracking and expedited review, they should contact Senior Deputy Editor Dr. Cynthia Mulrow (cmulrow@acponline.org) or Executive Deputy Editor Dr. Barbara Turner (baturner@mail.acponline.org) and provide an electronic version of the manuscript, the protocol and registry identification number, and a justification for expedited review.
Within 48 hours, 2 editors will judge whether a manuscript is eligible for expedited review. The review process takes approximately 3 weeks. The author will receive suggestions for revision no later than 1 month after receipt of the manuscript, and return of the revised manuscript is expected within 2 weeks. Accepted manuscripts are scheduled for publication immediately. In most instances, fast-track manuscripts are published electronically at www.annals.org within 2 weeks of acceptance, with print publication 2 months later.
Acknowledgement of Receipt TOP
We acknowledge all manuscripts and assign each a unique, confidential manuscript number. We provide all authors with instructions for checking the status of the manuscript online. To check the status of your manuscript online, click here.
Internal Review by Editors and Peer Review TOP
At least 1 Editor and 1 Associate Editor read each manuscript. Together, they decide whether to send the paper to outside reviewers. If a paper is rejected without external review, authors are notified electronically within 1 to 2 weeks of receipt. We retain copies of rejected manuscripts for 60 days, after which we delete them from our system.
We send about 50% of submitted papers for peer review, usually to at least 2 reviewers. The Editors select reviewers from an electronic database of about 13 000 reviewers. We do not send a manuscript to a reviewer who is affiliated with the same institution as any of the authors. We ask reviewers to declare potential conflicts of interest and to decline the opportunity to review if they think that a close personal or professional relationship with any of the authors could lead to a review that would be different than if no such relationship existed. If peer reviewers do not know whether a particular situation merits disqualification from the review process, they should contact the editors who will advise them about recusal on a case by case basis. Authors may list individuals that they do not want to be a reviewer, but must justify their requested exception in the cover letter.
Editors and associate editors discuss many of the papers that are peer reviewed at a weekly manuscript conference. Editors recuse themselves from discussing manuscripts and avoid participation in decisions about manuscripts if they have a close personal or professional relationship with any of the authors.
Acceptance or Rejection and Criteria for Editorial Decisions TOP
Annals can publish only a fraction of all papers submitted each year. In recent years, 13% of all submissions and 7% of Articles and Brief Communications were accepted. Editors judge the potential importance and newness of material and consider scientific rigor using established methodological criteria (See ACP Journal Club Basic Criteria at www.acpjc.org). They select manuscripts based on the strength of the paper compared with other papers under review, the need for Annals to represent a balanced picture of important advances in internal medicine, and the number of accepted papers in the paper’s category and topic area. Almost all papers that we accept require some editorial or statistical revision before publication. Of note, to check or clarify analyses and findings, editors may ask researchers to provide the raw data for their studies during review or at any time up to 5 years after publication in Annals.
We send the reviewers’ comments to authors whether or not we accept the article. On occasion, we reject an article but invite a resubmission that addresses specific concerns of the editors. We aim to accept a high percentage (at least three quarters) of these articles that we re-invite, and we specify conditions that the authors must meet before we will accept a re-invited manuscript. Upon resubmission, we assign reinvited manuscripts a new unique, confidential manuscript number. We determine whether to send the reinvited manuscript for repeated external peer review or internal editorial and statistical review on a case-by-case basis.
Submitting an Appeal TOP
Authors who think that their manuscripts were rejected wrongly may e-mail an appeal letter to the editor who handled the manuscript. The letter should detail the author’s concern and state how the manuscript could be revised or clarified to address key problems mentioned by editors and reviewers. The editors expect appeals infrequently and do not reverse their original decisions often. Many rejections involve editors’ judgments of priority that authors usually cannot address through an appeal. Editors only consider appeals that are submitted within 2 months of the manuscript’s rejection and consider appeals only once. Upon receiving the appeal, editors may confirm their decision to reject the manuscript, invite a revised manuscript, or seek additional peer review or statistical review of the original manuscript.
Manuscript Publication
TOP | Manuscript Preparation | Specific Article Types | Manuscript Processing | Manuscript Publication | Authorship Issues | Research/Publication Ethics | References | Appendix
Postacceptance Copy Editing TOP
All accepted manuscripts are subject to copy editing to improve clarity and achieve consistency of style and formatting of journal content. Authors will have the opportunity to approve revisions made during the copy editing process. Editors will work with authors to arrive at agreement when authors do not find the revisions acceptable, but Annals reserves the right not to publish a manuscript if discussion with the author fails to reach a solution that satisfies the editors.
National Institutes of Health-Funded Research Articles TOP
The American College of Physicians, publisher of Annals, supports authors’ adherence to the NIH Public Access Policy. Authors of articles reporting NIH-funded studies may submit to PubMedCentral (PMC) a document that contains the “accepted manuscript.” “Accepted manuscript” refers to the prepublication version for which Annals has issued a notice of final acceptance.
Neither the American College of Physicians nor Annals of Internal Medicine can assume responsibility for prepublication versions of articles. To limit confusion about multiple versions of article content, the “accepted version” submitted to PMC should prominently display the following disclaimer immediately following the title:
“This is the prepublication, author-produced version of a manuscript accepted for publication in Annals of Internal Medicine. This version does not include post-acceptance editing and formatting. The American College of Physicians, the publisher of Annals of Internal Medicine, is not responsible for the content or presentation of the author-produced accepted version of the manuscript or any version that a third party derives from it. Readers who wish to access the definitive published version of this manuscript and any ancillary material related to this manuscript (e.g., correspondence, corrections, editorials, linked articles) should go to www.annals.org or to the print issue in which the article appears. Those who cite this manuscript should cite the published version, as it is the official version of record.”
Authors are responsible for informing PMC that it should not make the accepted manuscript publicly available in the PMC repository until 6 months after the date of publication in Annals of Internal Medicine.
Authors should not submit copies of the final published version (e.g., PDF or html versions copied from www.annals.org) to PMC. This action would violate the American College of Physicians copyright.
| PubMedCentral Submission TOP | |||
| Article version | Definition | Copyright owner |
Annals permits author to send to PubMedCentral |
| Final accepted | Author manuscript accepted for publication by Annals, before final editing and formatting |
Annals | Yes |
| Final published | Article published in Annals, with final editing and formatting |
Annals | No |
Free Access Policy TOP
Annals gives free access to the following content:
- Articles published early at www.annals.org prior to publication in the print version of Annals
- Articles that the editors determine to be of immediate importance to the public
- Clinical Guidelines and Summaries for Patients (use the advanced search page to search Annals for only these articles)
- PDFs of all articles from 1999 to 6 months before the current issue
- Full text (HTML) of all articles from 1993 to 1998 (these issues do not contain PDFs of articles)
- Any article if the user is:
- An Annals subscriber
- A member of the American College of Physicians
- From a country in the HINARI initiative or in the World Bank’s list of “Lower-income economies”
Prepublication Policy TOP
Annals publishes on the first and third Tuesday of each month. Annals sends advance copies of the journal to members of the news media the week before publication. Reporters may not publish stories based on this information until 5:00 p.m. (U.S. Eastern time) of the day before the date of publication of an issue. Authors are free to discuss their research with representatives of the media but should not distribute copies of papers accepted for publication in Annals. They should consent to be interviewed only if the reporter agrees to abide by the embargo and will not publish until after the embargo period.
Providing copies of manuscripts or detailed information to media, manufacturers, or government agencies of scientific information described in a paper or a Letter to the Editor that has been accepted but not yet published violates the policies of Annals and many other journals. Annals may grant an exception to this rule when the paper or letter describes major therapeutic advances, public health hazards (such as serious adverse effects of drugs, vaccines, other biological products, or medical devices), or reportable diseases. Prepublication disclosure as part of sworn testimony before legislative or judiciary bodies may also be acceptable. Authors should discuss any possible prepublication disclosure with the Editors in advance and obtain their agreement.
Scheduling of Accepted Papers and Proofs TOP
We notify authors when they can expect to receive proofs. Authors who think they may not be able to examine proofs within 48 hours of receiving them should call the Editorial Production Supervisor (215-351-2633) to designate a colleague who will review proofs.
Ordering Reprints TOP
We send a form for ordering reprints to authors when we send the proofs of the edited manuscript. If the author does not return the form to the address listed on the form, we will not order reprints. Third parties who wish to order reprints of published articles may do so by contacting Helen Canavan (hcanavan@acponline.org).
Authorship Issues
TOP | Manuscript Preparation | Specific Article Types | Manuscript Processing | Manuscript Publication | Authorship Issues | Research/Publication Ethics | References | Appendix
Authorship: Criteria and Policy
Authorship implies accountability. Listed authors must have contributed directly to the intellectual content of the paper, and the corresponding author should list the specific contributions of all authors in the appropriate section of the Authors’ Form. Authors should meet all of the following criteria, thereby allowing persons named as authors to accept public responsibility for the content of the paper.
- Conceived and planned the work that led to the article or played an important role in interpreting the results, or both.
- Wrote the paper and/or made substantive suggestions for revision.
- Approved the final version.
Holding positions of administrative leadership, contributing patients to a study, and collecting and preparing the data for analysis, however important to the research, are not, by themselves, criteria for authorship. The manuscript should note people who made substantial, direct contributions to the work but did not meet the criteria for authorship in the Acknowledgments section, and should provide a brief description of their contributions.
Medical writers and industry employees can be legitimate contributors, and their roles, affiliations, and potential conflicts of interest should be described when submitting manuscripts (Daskalopoulou, Jacobs). These writers should be acknowledged on the byline or in the Acknowledgments section in accord with the degree to which they contributed to the work reported in the manuscript. The editors consider failure to acknowledge these contributors ghostwriting, which is contrary to Annals' editorial policy.
Authorship: Declaration Processes TOP
All authors of papers accepted for publication must electronically sign a form affirming that they have met the criteria for authorship, have agreed to be authors, and are aware of the terms of publication. We request that authors complete these forms when we suggest revisions to manuscripts. We do not require them when manuscripts are initially submitted. We also request that authors provide written permission from the individuals that they wish to list in the Acknowledgments section when we suggest revisions to manuscripts.
The corresponding author will serve as the first contact for all communication about manuscripts submitted to Annals, and it is this person’s responsibility to share all Annals communication with all of the authors. In addition, it is the corresponding author’s responsibility to respond to any questions regarding the integrity of the work, including but not limited to requests for study protocols or trial registry information, study data, and documentation of institutional review board approval. If the list of authors changes between submission and final acceptance of an article, it is the corresponding author’s responsibility to explain the changes to the editors in writing and to obtain written documentation that all of the authors (including deleted authors) approve of the author changes.
All authors, except U.S. government employees whose work was done as part of their official duties, must transfer copyright to the American College of Physicians, publisher of Annals. Transfer of copyright signifies transfer of rights for print publication; electronic publication; production of reprints, facsimiles, microfilm, or microfiche; or publication in a language other than English. We usually grant permission on request and without charge when authors ask to use portions of their work published in Annals for limited educational purposes and in other scholarly publications.
Conflict of Interest: Definition and Policy TOP
Conflict of interest exists when an author, editor, or peer reviewer has a competing interest that could unduly influence (or be perceived to do so) his or her responsibilities in the publication process. The potential for an author’s conflict of interest exists when he or she (or the author’s institution or employer) has personal or financial relationships that could influence (bias) his or her actions. These relationships vary from those with negligible potential to influence judgment to those with great potential to influence judgment. Not all relationships represent true conflict of interest. Conflict of interest can exist whether or not an individual believes that the relationship affects his or her scientific judgment.
Authors, editors, and peer reviewers must state explicitly whether potential conflicts do or do not exist. Academic, financial, institutional, and personal relationships (such as employment, consultancies, close colleague or family ties, honoraria for advice or public speaking, service on advisory boards or medical education companies, stock ownership or options, paid expert testimony, grants or patents received or pending, and royalties) are potential conflicts of interest that could undermine the credibility of the journal, the authors, and science itself.
Authors, editors, and peer reviewers must disclose their primary academic and institutional affiliations and all financial relationships that could be viewed as presenting a potential conflict of interest. These include, but are not limited to, any financial relationship that involves conditions or tests or treatments discussed in the manuscript and alternatives to the tests or treatments for those conditions. If persons are uncertain, they should err on the side of full disclosure. Disclosure of these relationships is essential not only for original research articles but also for editorials, letters, commentary, and review articles. Annals publishes author’s conflict of interest disclosures and discloses editor’s financial and academic relationships. Annals avoids publishing editorials, reviews, and guidelines authored by individuals with potential financial conflicts of interest but considers each such manuscript on a case-by-case basis.
Conflict of Interest: Disclosure Processes TOP
At the time of manuscript submission, Annals of Internal Medicine requires corresponding authors to summarize all authors’ conflict of interest disclosures. (We also require conflict of interest disclosures from members of panels that help formulate consensus or guideline recommendations, even if those contributors are not named authors on the consensus or guideline statement.) We provide the summary information collated by the corresponding author to editors and peer reviewers. If editors later invite the authors to revise a manuscript after peer review, we ask each author, including the corresponding author, to individually complete online Conflict of Interest Disclosure Statements. Relationships that we prompt authors to report include most of those mentioned above. We require reporting of the relationships if they occurred within the following time frames: a) during the year preceding the start of the development of the work reported in the manuscript up through acceptance for publication or b) during the five year period preceding acceptance for publication if this time frame is longer than the time frame described in a. We also require reporting any pertinent pending grants and drug approval or patent applications expected within 1 year following the manuscript acceptance date. At the time of manuscript acceptance, we ask authors to confirm and update, if necessary, their disclosure statements.
As part of the initial submission process, we also ask the corresponding author to attest that the authors had access to all the study data, take responsibility for the accuracy of the analysis, and had authority over manuscript preparation and the decision to submit the manuscript for publication. We do not consider an article unless the corresponding author makes this attestation on behalf of the authors. In addition, in the Methods section of the text, authors must state the funding source for the work and describe the role(s) of the funding organization in the design of the study; the collection, analysis, and interpretation of the data; and the decision to approve publication of the finished manuscript. If the funding source had no such involvement, the authors should state that.
Conflict of Interest: Investigation Processes TOP
Readers who believe that authors of articles published in Annals have neglected to disclose potential conflicts of interest should notify the journal about their concerns by either submitting a “rapid response” using the electronic system that is available for all published articles or contacting the editors in writing. Either form of communication should include the following information: name and contact information of person raising the concern, author’s name, title of article, nature of the relationship that the readers believe the authors failed to disclose including the company name if pertinent, and a description of how they became aware of the relationship. Readers should be aware that concerns raised in a rapid response are available not only to the editors but also to the authors and to other readers. Because erroneous allegations can harm the reputation of those named, those who raise such concerns should do so only after carefully checking to be sure the relationship they have identified is correct and is one that Annals policy requires authors to report.
The editors will respond to concerns about failure to disclose potential conflicts of interest by promptly investigating the potential conflict using publicly available means (e.g., internet searches, searching company and university web sites, examination of disclosures included in other published articles) and by asking the relevant authors for information about the matter. We will also alert all co-authors of the relevant manuscript about the concern and ask them to confirm their own conflict disclosures. The editors will directly notify the reader who raised the concern about the outcome of the investigation as soon as it is complete. If the editors verify that there was an undisclosed conflict of interest, Annals will publish a correction in the print journal and on www.annals.org that will be electronically linked to the relevant article.
Research/Publication Ethics
TOP | Manuscript Preparation | Specific Article Types | Manuscript Processing | Manuscript Publication | Authorship Issues | Research/Publication Ethics | References | Appendix
Confidentiality
The staff at Annals keeps author correspondence confidential, unless it is intended for publication (e.g., as a rapid response or letter to the editor). We also ask that authors and reviewers keep editorial correspondence confidential, and that authors refrain from sharing either the correspondence itself or the essence of its content with individuals who are not their collaborators. We ask authors to maintain this confidentiality about correspondence both before and after any final publication of their manuscript. Maintaining such confidentiality helps ensure that editors can offer advice that is in the best interests of authors’ papers without concern for how it might be considered or used by others.
Duplicate Publication or Submission
We ask that authors give full details on any possible previous or duplicate publication of any content of the manuscript in a cover letter. Previous publication of a small fraction of the content of a manuscript does not necessarily preclude its being published in Annals, but the Editors need information about previous publication when deciding how to use space in the journal efficiently; they regard authors’ failure to disclose possible prior or concurrent publication as a breach of scientific ethics (see Annals Policy on Prepublication Release of Information). We usually do not consider abstracts, posters, monographs, or detailed technology reports as duplicate prior publications that preclude submission. We usually deem other duplicative material (e.g., articles, reviews, perspectives) that is submitted, in press, or published in another peeryreviewed, easily accessible journal or source (e.g., The Cochrane Library) as prior work that precludes publication in Annals. Please attach a copy of any document that might be considered a previous publication at initial submission. If at any time the author submits to another journal a manuscript or Letter to the Editor that is under review by Annals, the author must inform the Annals Editors.
IRB Approval and Consent TOP
Research that involves human participants includes investigations that use only human blood, tissue, or medical records. The authors must confirm review of the study by the appropriate institutional review board or affirm that the protocol is consistent with the principles of the Declaration of Helsinki (see World Medical Association). If the authors did not obtain institutional review board approval before the start of the study, they should so state and explain the circumstances. If the study was exempt from review, the authors must state that such exemption complied with the policy of their local institutional review board. They should affirm that study participants gave their informed consent or state than an institutional review board approved conduct of the research without explicit consent from the participants. If patients are identifiable from illustrations, photographs, pedigrees, case reports, or other study data, the authors must submit the release form for each such individual (or copies of the figures with the appropriate release statement) giving permission for publication with the manuscript. Consult the Research section of the American College of Physicians Ethics Manual for further information.
Reproducible Research TOP
To encourage transparency and reproducible research (Peng, Domenici, Zeger), Annals will publish a statement with every original research article (Article or Brief Communication) indicating the authors willingness to share the following items with the public:
- Study protocol (original and amendments)
- Statistical code used to generate results
- Dataset from which the results were derived
Annals does not require the sharing of these items but we do require authors to state their willingness to share, and any conditions for sharing. Access to these items may range from completely unrestricted (e.g., free availability of all the items via posting on an open-access Web site) to restricted (e.g., availability of certain portions of the items to approved individuals through written agreements with the author or research sponsor).
Scientific Misconduct TOP
In addition to breaches in procedures related to human subjects, research misconduct includes issues related to the fabrication or falsification of data, plagiarism, theft of ideas, duplicate publication, misrepresentation of author contributions, and failure to disclose potential financial conflicts of interest. Should the Editors suspect research misconduct related to manuscripts submitted for review, the journal reserves the right to notify and forward the submitted manuscript to the chief executive officer and/or dean of the sponsoring institution, the funding institution, or other appropriate authority for investigation. Annals recognizes the responsibility to notify the appropriate authorities but does not undertake the actual investigation or make determinations of misconduct. The editors will notify the authors of the journal’s intention to report a suspicion of research misconduct.
References
TOP | Manuscript Preparation | Specific Article Types | Manuscript Processing | Manuscript Publication | Authorship Issues | Research/Publication Ethics | References | Appendix
Badgett B, Berkwits M, Mulrow C. Scholarship erosion [Editors’ response to letter]. Available at www.annals.org/cgi/eletters/142/5/389.
Bailar JC 3rd, Mosteller F. Guidelines for statistical reporting in articles for medical journals. Amplifications and explanations. Ann Intern Med. 1988;108:266-73. [PMID: 3341656] Medline
Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. Towards a complete and accurate reporting of studies of diagnostic accuracy: The STARD Initiative. Ann Intern Med. 2003;138:40-4.[PMID:12513043] Medline - Annals.org
Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Ann Intern Med. 2003;138:W1-12.[PMID:12513067] Medline - Annals.org
Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, Lijmer JG, Moher D, Rennie D, de Vet HC; Standards for Reporting of Diagnostic Accuracy. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy. Clin Chem. 2003;49:1-6. [PMID: 12507953] Medline
Isabelle Boutron, MD, PhD; David Moher, PhD; Douglas G. Altman, DSc; Kenneth F. Schulz, PhD, MBA; Philippe Ravaud, MD, PhD, for the CONSORT Group Extending the CONSORT Statement to Randomized Trials of Nonpharmacologic Treatment: Explanation and Elaboration. Ann Intern Med. 2008;148:295-309. Annals.org
Campbell MK, Elbourne DR, Altman DG; CONSORT group. CONSORT statement: extension to cluster randomised trials. BMJ. 2004;328:654-5. [PMID: 15031246] Medline
Cook DJ, Mulrow CD, Haynes RB. Systematic reviews: synthesis of best evidence for clinical decisions. Ann Intern Med. 1997;126:376-80. [PMID: 9054282] Medline - Annals.org
CBESMC - Council of Biology Editors Style Manual Committee. Scientific Style and Format: The CBE Manual for Authors, Editors, and Publishers. 6th ed. New York: Cambridge Univ Pr; 1994. ISBN: 0521471540
Daskalopoulou SS, Mikhailidis DP. The involvement of professional medical writers in medical publications [Editorial]. Curr Med Res Opin. 2005;21:307-10. [PMID: 15802002] Medline
Des Jarfais DC, Lyles C, Crepez N, TREND Group. Improving the reporting quality of nonrandomized evaluations of behavioral and public health interventions: The TREND statement. Am J Public Health, 2004;94:361-7. [PMID: 14998794] Medline
Editors. Reviews: making sense of an often tangled skein of evidence. Ann Intern Med. 2005;142(12 Pt 1):1019-20. [PMID: 15968018] Medline - Annals.org
Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356:1255-9. [PMID: 11072960] Medline
von Elm E, Altman DG, Egger M, Pocock SJ, Gxtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007;147:573-7. [PMID: 17938396] Medline - Annals.org
Gagnier JJ, Boon HJ, Rochon PJ, Moher DJ, Barnes JJ, Bombardier CJ. Reporting Randomized, Controlled Trials of Herbal Interventions: An Elaborated CONSORT Statement. Ann Intern Med 2006 144;5:364-367. [PMID: 16520478] Medline - Annals.org
Gopen GD, Swan JA. The science of scientific writing. Am Sci. 1990;78:550-8. Google Scholar
GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ 2004;328:1490-1494. [PMID: 15205295] Medline
Haynes RB, Mulrow CD, Huth EJ, Altman DG, Gardner MJ. More informative abstracts revisited. Ann Intern Med. 1990;113:69-76.[PMID: 2190518] Medline
Hopewell S, Clarke M, Moher D, Wager E, Middleton P, et al. CONSORT for Reporting Randomized Controlled Trials in Journal and Conference Abstracts: Explanation and Elaboration. PLoS Med 5(1). e20 doi:10.1371/journal.pmed.0050020. [PMID: 18215107] Medline
Huth EJ. Medical Style and Format. Philadelphia: ISI Pr; Baltimore MD: Williams & Wilkins; 1987. ISBN: 0894950630
Ioannidis JP, Evans SJ, Gotzsche PC, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med. 2004;141(10):781-8. [PMID: 15545678] Medline - Annals.org
ICMJE - International Committee of Medical Journal Editors. Uniform requirements for manuscripts submitted to biomedical journals. Ann Intern Med.1997;126(1):36-47. [PMID: 8992922] Medline - Annals.org
ICMJE - International Committee of Medical Journal Editors. Uniform requirements for manuscripts submitted to biomedical journals. Available at www.icmje.org. Accessed 6 February 2006.
Jacobs A, Wager E. European Medical Writers Association (EMWA) guidelines on the role of medical writers in developing peer-reviewed publications. Curr Med Res Opin 2005;21(2):317-321. [PMID: 15802003] Medline
Laine C, Goodman SN, Griswold M, Sox HC. Reproducible research: moving towards research the public can really trust. Ann Intern Med. 2007;146(8):450-53. [PMID: 17339612] Medline - Annals.org
Lang TA, Secic M. How To Report Statistics in Medicine. Philadelphia: American Coll of Physicians; 1997. ISBN: 0943126444
Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Intern Med. 2001;134(8):657-62. [PMID: 11304106] Medline - Annals.org
Moher D, Liberati, A, Tetzlaff J, Altman DG, PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. Ann Intern Med. 2009; 151:264-269 - Annals.org
Mulrow CD, Thacker SB, Pugh JA. A proposal for more informative abstracts of review articles. Ann Intern Med. 1988; 108:613-5 [PMID: 3348568] Medline
Peng RD, Domenici F, Zeger SL. Reproducible epidemiologic research. American Journal of Epidemiology. 2006;163(9):783-789. [PMID: 16510544] Medline
Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJ; CONSORT Group. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA. 2006;295:1152-60. [PMID: 16522836] Medline
Philips Z. Ginnelly L. Sculpher M. Claxton K. Golder S. Riemsma R. Woolacoot N. Glanville J. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technology Assessment (Winchester, England). 2004;8(36):iii-iv, ix-xi, 1-158. [PMID: 15361314] Medline
Sculpher M. Fenwick E. Claxton K. Assessing quality in decision analytic cost-effectiveness models. A suggested framework and example of application. Pharmacoeconomics. 2000;17(5):461-77. [PMID: 10977388] Medline
Shiffman RN, Shekelle P, Overhage JM, Slutsky J, Grimshaw J, Deshpande AM. Standardized reporting of clinical practice guidelines: A proposal from the Conference on Guideline Standardization. Ann Intern Med. 2003;139:493-8. [PMID: 13679327] Medline - Annals.org
Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276:1339-41. [PMID: 8861994] Medline
STROBE Group. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE). 2005. www.strobe-statement.org. Accessed 6 February 2006.
Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008-12. [PMID: 10789670] Medline
Vandenbroucke JP, von Elm E, Altman DG, Gxtzsche PC, Mulrow CD, Pocock SJ, et al.; STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Ann Intern Med. 2007;147:W163-94. [PMID: 17938389] Medline - Annals.org
Weinstein MC. O’Brien B. Hornberger J. Jackson J. Johannesson M. McCabe C. Luce BR. ISPOR Task Force on Good Research Practices--Modeling Studies. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies. Value in Health. 2003;6(1):9-17. [PMID: 12535234] Medline
World Medical Association. World Medical Association Declaration of Helsinki: Recommendations Guiding Physicians in Biomedical Research Involving Human Subjects [Declaration of Helsinki] JAMA. 1997;277:925-6. [PMID: 9062334] Medline
Young DS, Huth EJ. SI Units for Clinical Measurement. Philadelphia: American Coll of Physicians; 1998. ISBN: 0943126517
Appendix
TOP | Manuscript Preparation | Specific Article Types | Manuscript Processing | Manuscript Publication | Authorship Issues | Research/Publication Ethics | References | Appendix
Sample References
Journals
1. Standard article (List all authors when there are 6 or fewer; when there are 7 or more authors, list only the first 6 and add “et al.”)
Vega KJ, Pina I, Krevsky B. Heart transplantation is associated with an increased risk for pancreatobiliary disease. Ann Intern Med. 1996;124:980-3.
2. Corporate author
Clinical exercise stress testing. Safety and performance guidelines. The Cardiac Society of Australia and New Zealand. Med J Aust. 1996;164:282-4.
3. Supplement
Shen HM, Zhang QF. Risk assessment of nickel carcinogenicity and occupational lung cancer. Environ Health Perspect 1994;102(Suppl 1):275-82.
4. Special format (also applies to abstracts and editorials)
Enzensberger W, Fischer PA. Metronome in Parkinson’s disease [Letter]. Lancet. 1996;347:1337.
Books
List all authors or editors when 6 or fewer; when there are 7 or more authors, list only the first 6 and add “et al.”
1. Author
Ringsven MK, Bond D. Gerontology and Leadership Skills for Nurses. 2nd ed. Albany, NY: Delmar; 1996.
2. Editors
Norman IJ, Redfern SJ, eds. Mental Health Care for Elderly People. New York: Churchill Livingstone; 1996.
3. Chapter in a book
Phillips SJ, Whisnant JP. Hypertension and stroke. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis, and Management. 2nd ed. New York: Raven Pr; 1995:465-78.
4. Published proceedings paper
Bengtsson S, Solheim BG. Enforcement of data protection, privacy and security in medical informatics. In: Lun KC, Degoulet P, Piemme TE, Rienhoff O, eds. MEDINFO 92. Proceedings of the 7th World Congress on Medical Informatics; 6-10 September 1992; Geneva, Switzerland. Amsterdam: North-Holland; 1992:1561-5.
Other Citations in Reference List
1. In press (must have journal title)
Leshner AI. Molecular mechanisms of cocaine addiction. N Engl J Med. 1996; [In press].
2. Magazine article
Roberts JL. Villain or victim? Newsweek. 1996;4 Nov:40-1.
In-Text Citations of Unpublished Material (to be placed within parentheses)
1. Personal communication
(Strott CA, Nugent CA. Personal communication)
2. Unpublished papers
(Lerner RA, Dixon FJ. The induction of acute glomerulonephritis in rats. In preparation)
(Smith J. New agents for cancer chemotherapy. Presented at the Third Annual Meeting of the American Cancer Society, 13 June 1983, New York)
Citations of Electronic References
Cisler S. MediaTracks. Public Access Comput Syst Rev [serial on-line] 1990;109-15. Accessed at Public Access Computer Systems Forum PACS-L at www.pubaccess.com on 29 November 1997.
